Drug Trial Radar · NCT05724693
Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function
Last checked: Nov 20, 2026Latest source record: Jul 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Jan 30, 2023
Primary completion
Apr 23, 2024
Study completion Apr 23, 2024
Sponsor
- Lead sponsor
- Atea Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Bemnifosbuvir After a Single Dose
Conditions
- Healthy Volunteer
- Hepatic Impairment
Interventions
Bemnifosbuvir (BEM)Drug
Day 1: A single dose of BEM will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK) of BEM Maximum plasma concentration (Cmax)Time frame: Day 1
- Pharmacokinetics (PK) of BEM Area under the plasma concentration-time curve (AUC)Time frame: Day 1
- Pharmacokinetics (PK) of BEM AUCTime frame: Day 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Atea Study Site Orlando Clinical Research Center
Orlando, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.